U.S. Markets close in 2 hrs 3 mins
  • S&P 500

    4,134.77
    +6.78 (+0.16%)
     
  • Dow 30

    33,609.05
    -136.35 (-0.40%)
     
  • Nasdaq

    13,955.78
    +105.78 (+0.76%)
     
  • Russell 2000

    2,215.39
    -18.40 (-0.82%)
     
  • Crude Oil

    60.10
    +0.40 (+0.67%)
     
  • Gold

    1,747.10
    +14.40 (+0.83%)
     
  • Silver

    25.41
    +0.54 (+2.18%)
     
  • EUR/USD

    1.1946
    +0.0028 (+0.2389%)
     
  • 10-Yr Bond

    1.6230
    -0.0520 (-3.10%)
     
  • Vix

    16.64
    -0.27 (-1.60%)
     
  • GBP/USD

    1.3743
    +0.0001 (+0.0096%)
     
  • USD/JPY

    109.0900
    -0.2860 (-0.2615%)
     
  • BTC-USD

    63,353.59
    +3,330.41 (+5.55%)
     
  • CMC Crypto 200

    1,357.22
    +63.23 (+4.89%)
     
  • FTSE 100

    6,890.49
    +1.37 (+0.02%)
     
  • Nikkei 225

    29,751.61
    +212.88 (+0.72%)
     

Craig Johnson Is The Independent Director of Odonate Therapeutics, Inc. (NASDAQ:ODT) And Just Spent US$51k On Shares

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Even if it's not a huge purchase, we think it was good to see that Craig Johnson, the Independent Director of Odonate Therapeutics, Inc. (NASDAQ:ODT) recently shelled out US$51k to buy stock, at US$17.00 per share. Nevertheless, it only increased their shareholding by a minuscule percentage, and it wasn't a massive purchase by absolute value, either.

Check out our latest analysis for Odonate Therapeutics

Odonate Therapeutics Insider Transactions Over The Last Year

In fact, the recent purchase by Craig Johnson was the biggest purchase of Odonate Therapeutics shares made by an insider individual in the last twelve months, according to our records. That implies that an insider found the current price of US$19.20 per share to be enticing. Of course they may have changed their mind. But this suggests they are optimistic. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. In this case we're pleased to report that the insider bought shares at close to current prices. Craig Johnson was the only individual insider to buy during the last year.

The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
insider-trading-volume

Odonate Therapeutics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership of Odonate Therapeutics

For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 2.2% of Odonate Therapeutics shares, worth about US$16m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Do The Odonate Therapeutics Insider Transactions Indicate?

It is good to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Insiders likely see value in Odonate Therapeutics shares, given these transactions (along with notable insider ownership of the company). In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Odonate Therapeutics. At Simply Wall St, we found 3 warning signs for Odonate Therapeutics that deserve your attention before buying any shares.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.